AzTrials
AzTrials

FibromyalgiaPhase 4NFRNCT00965601

A Pilot Study on the Use of Nociceptive Flexion Reflex for Fibromyalgia

A Phase 4 study testing Cognitive Behavioral Therapy in people with Fibromyalgia, run by Indiana University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The investigators are doing this study to better understand the role of the central nervous system in processing painful stimuli in patients with fibromyalgia. Specifically, the investigators would like to know whether the central nervous system processing of painful stimuli changes with time and with talk therapy. Read more about this study

Who is it for?
Ages 18 to 65 years, women only
Conditions the study is for
Fibromyalgia
What is being tested?
Cognitive Behavioral Therapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteUnited States
Study dates
Jul 2008to Aug 2009
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 1. Female volunteers who have been diagnosed with fibromyalgia by a rheumatologist.
  • 2. Overall body pain average score ≥ 4
  • 3. Age range: 18 to 65 years old
  • 4. You must be on stable doses of anyone of these fibromyalgia-related medications for at least 4 weeks: cyclobenzaprine, tramadol, gabapentin, pregabalin, amitriptyline, nortriptyline, trazodone, sertraline, fluoxetine, paxil, remeron, venlafaxine and duloxetine.
  • 5. Willingness to restrict any change (add or switch or change in the dose) of any fibromyalgia-related medication for 12 weeks.

Who cannot join

  • 1. Volunteers who have long-standing history of diabetes (> 2 years), or have been diagnosed with any type of peripheral neuropathy.
  • 2. Have a prior history of myocardial infarction (heart attack) or unstable angina or other heart arrhythmias.
  • 3. Have been diagnosed with multiple sclerosis or any other demyelinating disorder.
  • 4. Have planned to undergo an elective surgery over the next 12 weeks.
  • 5. Have other major rheumatic conditions (i.e. rheumatoid arthritis, systemic lupus erythematosus, scleroderma and other connective tissue disease)
  • 6. Are currently pregnant or actively trying to become pregnant

Trial locations and contacts

1 site in 1 country.

United States1 site
  • National Institute of Fitness and Sport; IUPUI Campus

    Indianapolis, Indiana, 46202

Other trials in United States

About this study

The investigators are doing this study to better understand the role of the central nervous system in processing painful stimuli in patients with fibromyalgia. Specifically, the investigators would like to know whether the central nervous system processing of painful stimuli changes with time and with talk therapy. In addition, the investigators are investigating how changes in your fibromyalgia symptoms may affect certain markers or proteins in your blood.

Read the detailed description

Overall Design

Female patients with FM will be enrolled in this 12-week prospective cohort study. To effect change in patient's symptoms, subjects (n=30) will be randomized to receive six sessions of phone-based cognitive behavioral therapy (CBT) or to 'usual' care. CBT will be provided from week 1 (baseline) to week 6. Outcome assessments (i.e., self-report symptom questionnaires, plasma neuropeptide levels and NFR) will be performed at baseline, week 6 and week 12. Subjects who not complete all three testing phases of the study will be reported as withdraws, and will be replaced as needed until a total of 30 volunteers have completed this study:

Volunteers will be asked to visit the Fibromyalgia Clinical Research Center on 3 different occasions: baseline (Screening), week 6, and week 12.

During the first visit subjects will be randomly assigned to one of two groups. Similar to flipping a coin, you have a 50% chance of being assigned to either one of two groups: a) telephone-based educational instruction group or b) usual care group. Subjects who are randomly assigned to educational instruction group will receive one phone call per week for the first six weeks of the study. During the phone conversation, you will receive instructions in managing your pain. If subjects are assigned to the educational instruction group, subjects must agree to allow us to audiotape the telephone conversation. Audio-taping the telephone conversations will help us give you the highest quality of instruction. On the other hand, subjects assigned to the usual care group will receive no telephone calls from the research team.

During each visit subjects will be asked to do the following:

  1. Complete a comprehensive questionnaire (computer-based or the traditional paper and pen format) in regard to how fibromyalgia affects your daily living. Risks: You may feel uncomfortable or care not to answer a particular question. To minimize these risks, you can tell the researcher that you feel uncomfortable or do not wish to answer the question.
  2. Provide a blood sample (10 ml).The purpose or this blood test is to examine changes in certain blood markers in relation to your changes in your symptoms Risks: The physical risks associated with participation in this study are with the blood draw. The process of drawing blood may cause bleeding, bruising, pain, lightheadedness, and some minor swelling around the area of the needle stick. Occasionally an infection or bleeding may develop where the needle was placed in the vein. To minimize these risks, the blood specimen will be obtained by experienced technicians.
  3. Undergo nociceptive flexion reflex (NFR) testing. This test examines how your body responds to painful stimuli. To begin each testing session, electrodes used to measure the nociceptive flexion reflex will be attached to your left leg. To measure the reflex, we will administer a series of electrical stimuli to the ankle of your left foot. After each stimulus you will be asked to rate the stimulus intensity using a scale with anchors of 0 (no sensation), 50 (pain threshold), and 100 (maximum tolerable). This procedure is used to determine the intensity of stimulus required to elicit a nociceptive flexion reflex response from your left hamstring muscle. This reflex is so small that you may not even notice any activity in your leg muscles. The intensity of electrical stimuli will be increased slowly until a reflex response is shown, but the intensity will NEVER exceed that which you rate as a "100" (maximum tolerable). At the higher intensities, the electrical stimulus is described by others as feeling like a "brief pinprick" or "carpet shock".

We will use the same procedure to assess your pain tolerance threshold for electrical stimulation to your ankle. Stimulus intensity will be increased slowly and you will be asked to rate each stimulus on the 0-100 scale. The procedure will end as soon as you provide a stimulus intensity rating of "100" (maximum tolerable).

Risks: The nociceptive flexion reflex procedure is likely to elicit temporary discomfort, increases in heart rate and blood pressure as well as sensations of discomfort or pain. Further, preparation of the skin required to apply electrodes may be mildly irritating or uncomfortable, and may leave behind some redness of the skin that could require a few days to heal. To minimize these risks, only well trained technicians will conduct this test. It is important to note that this test is similar to an EMG (electromyogram) study - a test commonly done in routine medical care.

Conditions
Fibromyalgia
Keywords
Fibromyalgia
Medical subject headings
Fibromyalgia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cognitive Behavioral TherapyBehavioural

    Subjects randomized to the Active Arm will receive workbook assignments a series of six phone intervention interviews of Cognitive Behavioral Therapy (CBT)

Study groups in NCT00965601
Study groupRoleWhat they receive
CTB GroupActive comparatorSubjects will receive workbook assignments a series of six phone intervention interviews of Cognitive Behavioral Therapy (CBT)
Receives: Behavioral: Cognitive Behavioral Therapy
Usual CareNo interventionSubjects will not receive any type of intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Aim 1: Test the feasibility and subject acceptability of a potentially objective tool (NFR) for measuring pain severity.

    Measured: Baseline, Week 9, and Week 12

Secondary outcomes (1)
  1. Aim 2: Determine the longitudinal relationships of changes in patients' symptoms with changes in plasma levels of neuropeptides and NFR pain threshold.

    Measured: Baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Aug 2009 (estimated)
  2. Study startJul 2008
  3. Primary completionJul 2009
  4. Study completionAug 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00965601
Sponsor's protocol ID
NFR 080554
Other IDs
IU Internally funded
Acronym
NFR
Status last verified
Aug 2009
First submitted
24 Aug 2009
Last updated
6 Apr 2012
Results posted
No
Data monitoring committee
No

Publications

  • Ang DC, Chakr R, Mazzuca S, France CR, Steiner J, Stump T. Cognitive-behavioral therapy attenuates nociceptive responding in patients with fibromyalgia: a pilot study. Arthritis Care Res (Hoboken). 2010 May;62(5):618-23. doi: 10.1002/acr.20119.

    PubMed 20191481

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Cognitive Behavioral Therapy in people with Fibromyalgia, run by Indiana University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Apr 2012. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Aim 1: Test the feasibility and subject acceptability of a potentially objective tool (NFR) for measuring pain severity. (time frame: Baseline, Week 9, and Week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00965601, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Apr 2012.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in